Patents by Inventor Hans van Eenennaam

Hans van Eenennaam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a sample
    Patent number: 11959924
    Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: April 16, 2024
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
  • ANTI-CD103 ANTIBODIES
    Publication number: 20230183354
    Abstract: The present invention relates to anti-CD 103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases. Also disclosed is an imaging agent comprising the anti-CD 103 antibody and a detectable label, wherein the antibody either does not block CD 103 binding to E-cadherin or at least partially blocks CD 103 binding to E-cadherin. The methods of treatment involve administering the anti CD 103 antibody which may be optionally coupled to a cytotoxic agent. Diseases to be treated include e.g. Hairy Cell leukemia, HCLv, intestinal and extraintestinal lymphomas, enteropathy-associated T-cell lymphoma (EATL), T-lymphoblastic leukemia/lymphoma (T-ALL), T-cell prolymphocytic leukemia (T-PLL), adult T cell leukemia/lymphoma (ATLL), mycosis fungoides (ME), anaplastic large cell lymphoma ALCL, cutaneous T-cell lymphoma (CTCL), Sezary Syndrome (SS), Alzheimer's disease, Parkinson's disease or multiple sclerosis.
    Type: Application
    Filed: April 30, 2021
    Publication date: June 15, 2023
    Applicants: SAIROPA B.V., RIJKSUNIVERSITEIT GRONINGEN, ACADEMISCH ZIEKENHUIS GRONINGEN
    Inventors: Marco DE BRUYN, Klaas Jan-Derek KOL, Hans Wilhelm NIJMAN, Hans VAN EENENNAAM,, Sander Martinus Johannes VAN DUIJNHOVEN
  • ANTI-SIRP ALPHA ANTIBODIES
    Publication number: 20220135677
    Abstract: The present invention relates to anti-SIRP? antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: January 14, 2022
    Publication date: May 5, 2022
    Applicant: SAIROPA B.V.
    Inventors: Hans VAN EENENNAAM, Andrea VAN ELSAS, Erik VOETS, Paul VINK, David Lutje HULSIK
  • ANTI-SIRP ALPHA ANTIBODIES
    Publication number: 20220135671
    Abstract: The present invention relates to anti-SIRP? antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: November 30, 2020
    Publication date: May 5, 2022
    Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans VAN EENENNAAM, Andrea VAN ELSAS, Erik VOETS, Paul VINK, David Lutje HULSIK
  • ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1
    Publication number: 20210403560
    Abstract: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
    Type: Application
    Filed: September 8, 2021
    Publication date: December 30, 2021
    Applicant: Merck Sharp & Dohme B.V.
    Inventors: Gregory John Carven, Hans van Eenennaam, Gradus Johannes Dulos
  • METHODS FOR PERFORMING EX VIVO DIAGNOSTIC TESTS FOR THE PRESENCE OF A PROLIFERATION-INDUCING LIGAND (APRIL) IN A HUMAN SAMPLE
    Publication number: 20210325404
    Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.
    Type: Application
    Filed: June 28, 2021
    Publication date: October 21, 2021
    Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
  • Antibodies to human programmed death receptor PD-1
    Patent number: 11117961
    Abstract: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: September 14, 2021
    Inventors: Gregory John Carven, Hans van Eenennaam, Gradus Johannes Dulos
  • ALTERED APRIL BINDING ANTIBODIES
    Publication number: 20210221900
    Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 22, 2021
    Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
  • Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a human sample
    Patent number: 11047864
    Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: June 29, 2021
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
  • Humanized antibodies which bind to human APRIL (“a proliferation-inducing ligand”)
    Patent number: 10961316
    Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: March 30, 2021
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
  • Anti-SIRP? antibodies
    Patent number: 10851164
    Abstract: The present invention relates to anti-SIRP? antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: December 1, 2020
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Erik Voets, Paul Vink, David Lutje Hulsik
  • Anti-HCTLA-4 antibodies
    Patent number: 10808030
    Abstract: The invention relates to new anti-hCTLA-4 antibodies that bind to a different epitope than prior art anti-CTLA4 antibodies, methods to produce these antibodies and therapeutic and diagnostic uses of these antibodies. These antibodies show a similar affinity for the CTLA4 antigen and they are also able to block the binding of CTLA4 to CD80 and/or CD86.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: October 20, 2020
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Joost Kreijtz, David Lutje Hulsik, Paul Vink
  • ANTI-CD27 ANTIBODIES
    Publication number: 20200131272
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: December 23, 2019
    Publication date: April 30, 2020
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • ALTERED APRIL BINDING ANTIBODIES
    Publication number: 20200079859
    Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.
    Type: Application
    Filed: August 12, 2019
    Publication date: March 12, 2020
    Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
  • Anti-CD27 antibodies
    Patent number: 10556957
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: February 11, 2020
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B. V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • Anti-PD-1 antibodies
    Patent number: 10494436
    Abstract: The present invention relates to anti-PD-1 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease. These antibodies have CDRs as provided in the enclosed sequences. Also part of the invention are nucleic acids encoding these antibodies, expression vectors comprising such nucleotide sequences and host cells that comprise said nucleotide sequences or expression vectors.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: December 3, 2019
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Joost Kreijtz, David Lutje Hulsik, Carlos Ricardo Rodrigues Dos Reis
  • ANTI-CD27 ANTIBODIES
    Publication number: 20190300618
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: September 25, 2017
    Publication date: October 3, 2019
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • Method of treating IgA nephropathy by administering humanized APRIL-binding antibodies
    Patent number: 10377830
    Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: August 13, 2019
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
  • METHOD FOR OBTAINING APRIL-BINDING PEPTIDES, PROCESS FOR PRODUCING THE PEPTIDES, APRIL-BINDING PEPTIDES OBTAINABLE WITH SAID METHOD/PROCESS AND USE OF THE APRIL-BINDING PEPTIDES
    Publication number: 20190170766
    Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.
    Type: Application
    Filed: September 11, 2018
    Publication date: June 6, 2019
    Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
  • COMBINING CD27 AGONISTS AND IMMUNE CHECKPOINT INHIBITION FOR IMMUNE STIMULATION
    Publication number: 20190135933
    Abstract: The present invention relates to treatments of conditions ameliorated by stimulation of an immune response, in particular by the stimulation of antigen-specific T-lymphocytes. Treatment of such conditions according to the invention is effected by the combination of an anti-human CD27 agonistic antibody together with a number of immune checkpoint inhibitors.
    Type: Application
    Filed: January 16, 2019
    Publication date: May 9, 2019
    Inventors: Hans Van Eenennaam, Andrea Van Elsas